| 注册
首页|期刊导航|医学新知|核受体结合SET结构域蛋白2在结直肠癌中的研究进展

核受体结合SET结构域蛋白2在结直肠癌中的研究进展

任鹏 刘彩霞

医学新知2026,Vol.36Issue(3):348-354,7.
医学新知2026,Vol.36Issue(3):348-354,7.DOI:10.12173/j.issn.1004-5511.202501037

核受体结合SET结构域蛋白2在结直肠癌中的研究进展

Research progress of nuclear receptor-binding SET domain protein 2 in colorectal cancer

任鹏 1刘彩霞2

作者信息

  • 1. 内蒙古医科大学第一临床医学院(呼和浩特 010059)
  • 2. 内蒙古医科大学附属医院肿瘤内科(呼和浩特 010050)
  • 折叠

摘要

Abstract

Colorectal cancer(CRC)is a highly prevalent and deadly gastrointestinal malignancy worldwide,driven by both genetic alterations and epigenetic reprogramming.The nuclear receptor-binding SET domain protein 2(NSD2)is a type of methyltransferase that catalyzes histone H3 Lysine 36 dimethylation(H3K36me2)as its core function,and is abnormally overexpressed in various tumors.Existing evidence suggests that NSD2 mainly functions in CRC through the pro cancer chain of"epigenetic writing-chromatin remodeling-transcriptional program rearrangement".In addition,NSD2 can amplify key signals such as metastasis-related signals,DNA damage repair,and stress adaptation pathways by methylating non histone substrates,and drive metabolic reprogramming,thereby promoting invasion and metastasis,treatment tolerance,and changes in the tumor microenvironment.In clinical practice,NSD2 has the potential to serve as a prognostic/therapeutic biomarker and epigenetic therapy target for CRC.This article focuses on the NSD2-H3K36me2 axis,reviews epigenetic regulatory mechanisms of NSD2 in CRC,its association with metabolism/microenvironment/therapeutic sensitivity,and the research progress on targeted inhibition and degradation strategies.It also proposes future key directions for translational research.

关键词

核受体结合SET结构域蛋白2/结直肠癌/表观遗传学/组蛋白甲基化

Key words

Nuclear receptor-binding SET domain protein 2/Colorectal cancer/Epigenetics/Histone methylation

分类

医药卫生

引用本文复制引用

任鹏,刘彩霞..核受体结合SET结构域蛋白2在结直肠癌中的研究进展[J].医学新知,2026,36(3):348-354,7.

基金项目

内蒙古自治区"草原英才"工程创新创业团队项目 ()

医学新知

1004-5511

访问量0
|
下载量0
段落导航相关论文